▎药明康德/报道合全药业宣布收购百时美施贵宝瑞士库威（Couvet）生产基地
美国纽约和中国上海，2021年2月2日 -- 百时美施贵宝（NYSE:BMY）和药明康德子公司合全药业今日联合宣布，合全药业将收购百时美施贵宝位于瑞士库威（Couvet）的生产基地。合全药业是全球领先的新药研发生产CDMO企业，收购完成后，库威工厂将成为合全药业在欧洲的首个生产基地，进一步拓展其平台能力与规模，助力合作伙伴加速新药研发进程，造福全球病患。在获得监管机构批准并满足惯例成交条件后，该交易预计于2021年第二季度完成。此后，合全药业将全面接管库威生产基地的硬件设施及运营管理，包括工厂、设备、技术和员工等。“库威生产基地在质量、安全性和生产效率等方面均达到世界一流水平。我们相信，合全药业将充分发挥该基地在规模和技术上的优势，继续为患者造福。”百时美施贵宝全球产品开发及供应链总裁Lou Schmukler表示，“此次交易对于我们全球生产网络的发展迭代至关重要，将更好地为公司的创新产品组合服务。瑞士始终是公司的战略要地，我们期望能够在纳沙泰尔（Neuchâtel）地区继续保持强劲的市场地位。”“欢迎库威生产基地加入合全药业的全球网络，我们与库威当地的人才团队拥有共同的‘客户第一、精益求精’的理念，非常期待与大家携手同行。”合全药业首席执行官陈民章博士表示：“我们希望通过此次收购，更好地为欧洲及全球客户赋能，助力更多新药、好药早日问世，造福全球病患。”在并购交易完成之前，库威生产基地仍在百时美施贵宝生产体系下运营。威廉博莱公司（William Blair & Company）担任百时美施贵宝的独家财务顾问。科文顿·柏灵律师事务所（Covington & Burling）担任法律顾问。库威（Couvet）生产基地坐落在瑞士纳沙泰尔州（Neuchâtel）。该基地拥有先进的生产能力，能够大规模商业化生产胶囊和片剂。该基地符合行业领先的能效和环保标准，能够满足未来可持续发展。百时美施贵宝是一家以“研发并提供创新药物，帮助患者战胜严重疾病”为使命的全球性生物制药公司。如需了解更多信息，请浏览百时美施贵宝中国官方网站www.bms.com.cn。合全药业是药明康德子公司，在全球多地设有研发及生产基地。合全药业服务于生命科学行业，拥有卓越的化学创新药研发和生产的能力和技术平台。作为全球新药合作研究开发生产领域（CDMO）的领军企业，合全药业致力于为全球合作伙伴提供从临床前到商业化，高效、灵活、高质量的一站式CMC（化学、生产和控制）解决方案。更多信息，请访问公司网站：www.STApharma.com.cn药明康德（股票代码：603259.SH/2359.HK）为全球生物医药行业提供全方位、一体化的新药研发和生产服务。通过赋能全球制药、生物科技和医疗器械公司，药明康德致力于推动新药研发进程，为患者带来突破性的治疗方案。本着以研究为首任，以客户为中心的宗旨，药明康德通过高性价比和高效的研发服务，助力客户提升研发效率，服务范围涵盖化学药研发和生产、细胞及基因疗法研发生产、医疗器械测试等领域。目前，药明康德的赋能平台正承载着来自全球30多个国家的4100多家合作伙伴的研发创新项目，致力于将更多新药、好药带给全球病患，早日实现“让天下没有难做的药，难治的病”的愿景。更多信息，请访问公司网站：www.wuxiapptec.com本新闻稿包含“前瞻性陈述”，该术语在有关药品研究、开发和销售的1995 年“私人证券诉讼改革法案”中定义。前瞻性陈述并未与历史或当前的现实严格关联。这种前瞻性声明是基于历史绩效以及公司未来财务结果、长期目标、计划和短期目标的期望和预估。这涉及内在风险、假设和不确定性，其中包括内在或外在因素，使得它们中的任何部分在未来几年可能出现延迟、偏离或改变，变得难以预计，可能会超出公司的控制范围，造成公司未来的财务结果、长期目标、计划和短期目标与该声明中的内容存在较大差异。这种风险、不确定性和其他事宜包括但不限于，能否与有关雇员代表机构就提议交易完成相关信息咨询程序；相关方是否满足达成既定交易的条件；百时美施贵宝延迟或无法实现预期交易利益；预期交易延迟或无法按照本新闻稿中所描述的按时完成。我们不会对任何前瞻性声明做出保证。本新闻稿中的前瞻性声明应与会对百时美施贵宝的业务和市场造成影响的诸多风险和不确定性综合考虑，尤其是在百时美施贵宝在Form 10-K中发布的2019年（结束于2019年12月31日）年报中给出的警戒性声明和风险因素讨论中确认的风险和不确定性。这部分内容后来在Form 10-Q的季报、Form 8-K的当前报告以及向美国证券交易委员会提交的其他文件中有更新。本新闻稿中包含的前瞻性声明是在本文件发布的日期前做出。除非适用法律另行规定，否则百时美施贵宝无义务对任何前瞻性声明进行公开更新或修订，无论是由于出现新信息，进一步的事件，环境改变或其他情况。
WuXi STA to Purchase Bristol Myers Squibb Manufacturing Facility in Couvet, SwitzerlandNEW YORK & SHANGHAI -- Bristol Myers Squibb (NYSE: BMY) and WuXi STA – a subsidiary of WuXi AppTec – today announced that WuXi STA has agreed to purchase Bristol Myers Squibb’s manufacturing facility in Couvet, Switzerland. The Couvet site will be the first facility in Europe for WuXi STA, a leading Contract Development and Manufacturing Organization. The acquisition will enhance WuXi STA’s existing capabilities while growing capacity to support its partners’ life-saving work.The companies anticipate completing the transaction by Q2 2021, subject to regulatory approvals and the satisfaction of other closing conditions. Upon closing, WuXi STA will acquire the Couvet site’s operations and assets, which include the plant and equipment, as well as a workforce with technical capabilities and expertise. “The Couvet site is a world-class facility designed for quality, safety, and efficiency, and we believe WuXi STA will be able to leverage the capacity and capabilities for its own operations as it continues to play a vital role for patients around the world,” said Lou Schmukler, President, Global Product Development and Supply, Bristol Myers Squibb. “This is an important step in the ongoing evolution of our manufacturing network to support our product portfolio. Switzerland remains an important strategic location for Bristol Myers Squibb, and we look forward to maintaining a strong presence in the Neuchâtel area.”“We are pleased to add the Couvet manufacturing facility to our growing global manufacturing site network and look forward to working with the talented team who share our focus on excellence and a patient-centered approach,” said Dr. Minzhang Chen, CEO of WuXi STA. “The acquisition will allow WuXi STA to better serve European markets and support our global customers to deliver innovative medicines and treatments to patients around the world.” The Couvet facility will continue to operate as part of Bristol Myers Squibb’s manufacturing network until the closing of the transaction.William Blair and Company, LLC, is serving as exclusive financial advisor to Bristol Myers Squibb, and Covington & Burling LLP is serving as legal counsel.About the Couvet Facility The Couvet site is located in the canton of Neuchâtel, Switzerland. The site is a state-of-the-art manufacturing facility with commercial-scale production capacity for capsule and tablet dosage forms. The facility was designed with industry leading energy efficiency and environmental standards and was constructed to accommodate future growth.About Bristol Myers Squibb Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram. WuXi STA, a subsidiary of WuXi AppTec, is a leading pharmaceutical development and manufacturing capability and technology platform company serving the life sciences industry, with global operations. As a premier Contract Development and Manufacturing Organization (CDMO), WuXi STA offers our worldwide partners efficient, flexible and high-quality solutions for integrated CMC (Chemical, Manufacturing, and Control) solutions from preclinical to commercial uses. For more information, please visit: http://www.STApharma.com and follow us on LinkedIn. WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable companies in the pharmaceutical, biotech and medical device industries worldwide to advance discoveries and deliver groundbreaking treatments to patients. As an innovation-driven and customer-focused company, WuXi AppTec helps our partners improve the productivity of advancing healthcare products through cost-effective and efficient, socially responsible and sustainable solutions. With industry-leading capabilities such as R&D and manufacturing for small molecule drugs, cell and gene therapies, and testing for medical devices, WuXi AppTec's open-access platform is enabling more than 4,100 collaborators from over 30 countries to improve the health of those in need – and to realize our vision that 'every drug can be made and every disease can be treated.' Please visit: www.wuxiapptec.comForward-Looking Statement This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 regarding, among other things, the research, development and commercialization of pharmaceutical products and the proposed transaction. All statements that are not statements of historical facts are, or may be deemed to be, forward-looking statements. Such forward-looking statements are based on historical performance and current expectations and projections about our future financial results, goals, plans and objectives and involve inherent risks, assumptions and uncertainties, including internal or external factors that could delay, divert or change any of them in the next several years, that are difficult to predict, may be beyond our control and could cause our future financial results, goals, plans and objectives to differ materially from those expressed in, or implied by, the statements. These risks, assumptions, uncertainties and other factors include, among others, the completion of the information and consultation processes with employees or relevant employee representative bodies, if any, in connection with the proposed transaction, the parties’ ability to satisfy certain closing conditions, any delay or inability of Bristol Myers Squibb to realize the expected benefits of the proposed transaction and that the proposed transaction will close on the terms or within the time frame described in this document. No forward-looking statement can be guaranteed. Forward-looking statements in this press release should be evaluated together with the many risks and uncertainties that affect Bristol Myers Squibb’s business and market, particularly those identified in the cautionary statement and risk factors discussion in Bristol Myers Squibb’s Annual Report on Form 10-K for the year ended December 31, 2019, as updated by our subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the Securities and Exchange Commission. The forward-looking statements included in this document are made only as of the date of this document and except as otherwise required by applicable law, Bristol Myers Squibb undertakes no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events, changed circumstances or otherwise.
|
